Literature DB >> 124347

Effect of deoxyuridine coadministration on toxicity and antitumor activity of fluorouracil and floxuridine.

J G Jato, L M Lake, E E Grunden, B M Johnson.   

Abstract

The addition of deoxyuridine (UDR) to fluorouracil (FU) or floxuridine (5-fluoro-2' deoxyuridine) (FUDR) produced a substantial increase in their toxicity in BDF1 mice. Antitumor assays using sarcoma 180 tumor-bearing mice showed a concomitant increase in tumor growth inhibition for the nucleoside-drug combination over identical doses of the single drug. However, no significant increase in antitumor activity with the combination treatment was demonstrated when equitoxic doses were given. Additional support for the therapeutic equality of the single and combination drug regimens was the similarity of the therapeutic indexes for each treatment regimen involving either fluorouracil or floxuridine. The results suggested that any therapeutic benefit achieved with the combination therapy could be duplicated with either fluorouracil or floxuridine at a higher dose.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 124347     DOI: 10.1002/jps.2600640609

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy.

Authors:  W Sadee; C G Wong
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

2.  Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents.

Authors:  S Suga; K Kimura; Y Yokoyama; K Isobe; Y Yoshida; T Takada; A Sato; T Kuwabara; H Iwase
Journal:  Gastroenterol Jpn       Date:  1982

3.  Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2'-tetrahydrofuryl)-5-fluorouracil.

Authors:  K Kimura; S Suga; T Shimaji; M Kitamura; K Kubo; Y Suzuoki; K Isobe
Journal:  Gastroenterol Jpn       Date:  1980
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.